Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
